Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Next Previous
Trial Profile

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary) ; Pegcetacoplan (Primary) ; Pembrolizumab (Primary) ; Bevacizumab
  • Indications Carcinoma; Clear cell sarcoma; Fallopian tube cancer; Malignant ascites; Ovarian cancer; Peritoneal cancer; Sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 18 Jun 2024 Planned End Date changed from 1 Dec 2025 to 30 Apr 2027.
  • 18 Jun 2024 Planned primary completion date changed from 1 Dec 2025 to 30 Apr 2026.
  • 03 May 2024 Primary safety end-point is added. Treatment arms are increased from 3 to 5 by the addition of two more experimental arms namely- Cohort 2B1 and cohort 2B2. Procedures of Biopsy, Biospecimen Collection are added to all the treatment arms.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top